Comparison · NCT00088413-c975b7b1
Colorectal Cancer Cohort vs Non-Colorectal Cancer Cohort: Number of Participants With an Positive Immune Response to Carcinoembryonic Antigen (CEA) Peptide and/or Protein in the Colorectal Cancer and Non-colorectal Cancer Cohort Post Vaccination
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Colorectal Cancer Cohort vs Non-Colorectal Cancer Cohort: Number of Participants With an Positive Immune Response to Carcinoembryonic Antigen (CEA) Peptide and/or Protein in the Colorectal Cancer and Non-colorectal Cancer Cohort Post Vaccination. Trial comparisons, record NCT00088413-c975b7b1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00088413-c975b7b1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.333 | 0.121 | 0.646 | wilson | |
| Risk in group 2 | 0.667 | 0.354 | 0.879 | wilson | |
| Risk difference, group 1 minus group 2 | -0.333 | -0.634 | 0.109 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.5 | 0.178 | 1.4 | log | |
| Odds ratio, group 1 over group 2 | 0.25 | 0.0352 | 1.77 | log | |
| Number needed to treat, for one fewer participant with the outcome on Colorectal Cancer Cohort than on Non-Colorectal Cancer Cohort | 3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Colorectal Cancer Cohort | Patients with histologically confirmed measurable or evaluable metastatic colorectal cancer or patients with surgically resected metastatic disease at high risk for recurrence who had completed at least one 5-fluorouracil/(5-FU) containing chemotherapy regimen (e.g., 5-fluorouracil/leucovorin (5-FU/LV) with or without either irinotecan or oxaliplatin or patients that have had an elevated serum CEA (\>5 ugg/L) at any point during their disease course who have failed or not a candidate for standard therapy. | 3 | 9 | OG000 |
| Group 2 | Non-Colorectal Cancer Cohort | Patients with histologically confirmed measurable or evaluable metastatic non-colorectal cancer or patients with surgically resected metastatic disease at high risk for recurrence who had completed at least one 5-fluorouracil/(5-FU) containing chemotherapy regimen (e.g., 5-fluorouracil/leucovorin (5-FU/LV) with or without either irinotecan or oxaliplatin or patients that have had an elevated serum CEA (\>5 ugg/L) at any point during their disease course who have failed or not a candidate for standard therapy. | 6 | 9 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With an Positive Immune Response to Carcinoembryonic Antigen (CEA) Peptide and/or Protein in the Colorectal Cancer and Non-colorectal Cancer Cohort Post Vaccination
- Description
Immune response in human leukocyte antigens (HLA)-A2 positive patients to carcinoembryonic antigen (CEA) was assessed by enzyme-linked immunospot assay (ELISPOT) analysis. A positive immune response was defined as a \>2x fold increase in the number of interferon gamma producing cells.
- Time frame
- post vaccination (up to Day 84)
- Population
- Overall number of participants analyzed reflects participants that are HLA-A2 positive.
Source ClinicalTrials.gov
Trial
- Title
- PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
- NCT number
- NCT00088413
- Phases
- PHASE1, PHASE2
- Conditions
- Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer
- Interventions
- PANVAC-V, PANVAC-F, Sargramostim (GM-CSF, Leukine)
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2019-04-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00088413?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00088413-c975b7b1